GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian Infants
Phase 3
Withdrawn
- Conditions
- DiphtheriaHaemophilus Influenzae Type bPoliomyelitisAcellular PertussisTetanus
- Interventions
- Biological: Infanrix-IPV/Hib
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2017-12-26
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT03128489
Compassionate Use for Subcutaneous (SC) Belimumab
- Conditions
- Systemic Lupus Erythematosus
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT03125486
- Locations
- 🇺🇸
GSK Investigational Site, Milwaukee, Wisconsin, United States
To Assess the Mildness of a Cosmetic Cleanser in Healthy Participants Using the Forearm-Controlled Application Technique (FCAT)
Not Applicable
Completed
- Conditions
- Skin Care
- Interventions
- Other: No TreatmentOther: Positive ControlOther: Test ProductOther: Reference Product
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2019-05-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 50
- Registration Number
- NCT03119688
- Locations
- 🇧🇷
GSK Investigational Site, Campinas, São Paulo, Brazil
Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Device: Seretide DISKUSDevice: Relvar ELLIPTADevice: BREEZHALERDevice: Symbicort TURBUHALERDevice: Incruse ELLIPTADevice: Spiriva HANDIHALERDevice: Anoro ELLIPTA
- First Posted Date
- 2017-04-14
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 450
- Registration Number
- NCT03114969
- Locations
- 🇬🇧
GSK Investigational Site, Sidcup, Kent, United Kingdom
To Characterize the Performance of the Nasal Dilator Strip in Lowering Nasal Resistance During Sleep, Promoting Nasal Route Breathing and Reducing the Signs and Symptoms of Sleep Disordered Breathing in a Group of Chronic Nocturnal Nasal Congestion Sufferers Who Report Trouble With Their Sleep.
Phase 2
Completed
- Conditions
- Sleep Disordered BreathingCongestion, Nasal
- Interventions
- Device: Prototype nasal dilator stripOther: No strip
- First Posted Date
- 2017-04-07
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 91
- Registration Number
- NCT03105297
- Locations
- 🇦🇺
Westmead Hospital, Westmead, New South Wales, Australia
Evaluation of the Cosmetic Benefit of a Skin Cream in Healthy Females With Mild to Advanced Photo-damaged Facial Skin Who Have Undergone a Glycolic Acid Facial Peel Procedure
Not Applicable
Completed
- Conditions
- Skin Care
- Interventions
- Other: Cream (Test product)Other: Cleanser (Reference Product)Other: Sunscreen (Reference Product)
- First Posted Date
- 2017-04-06
- Last Posted Date
- 2019-02-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 106
- Registration Number
- NCT03103906
- Locations
- 🇧🇷
GSK Investigational Site, Campinas, São Paulo, Brazil
Study of Mepolizumab Autoinjector in Asthmatics
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 159
- Registration Number
- NCT03099096
- Locations
- 🇬🇧
GSK Investigational Site, Southampton, United Kingdom
A Study to Evaluate of Cosmetic Benefit of a Moisturising Cream in People With Blemish Prone Skin
Not Applicable
Completed
- Conditions
- Skin Care
- Interventions
- Other: Washout / Standard CleanserOther: Positive control cleanserOther: Positive control moisturiserOther: Test product
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2020-02-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 157
- Registration Number
- NCT03093181
- Locations
- 🇧🇷
GSK Investigational Site, Valinhos, Brazil
A Study to Evaluate Safety and Immunogenicity of 1 Booster Dose of 1790GAHB Vaccine in Healthy Adults Primed With 3 Doses of 1790GAHB Vaccine in Study H03_01TP Compared to 1 Vaccination of 1790GAHB in Either Subjects Who Received Placebo in the Same Study or naïve Subjects Not Part of H03_01TP Study
Phase 1
Completed
- Conditions
- Dysentery, Bacillary
- Interventions
- Biological: GVGH Shigella sonnei 1790GAHB vaccine
- First Posted Date
- 2017-03-24
- Last Posted Date
- 2019-06-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 35
- Registration Number
- NCT03089879
- Locations
- 🇫🇷
GSK Investigational Site, Paris, France
Effect of Mepolizumab in Severe Bilateral Nasal Polyps
Phase 3
Completed
- Conditions
- Nasal Polyps
- Interventions
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 414
- Registration Number
- NCT03085797
- Locations
- 🇬🇧
GSK Investigational Site, Rotherham, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath